Location: United States, New Jersey, Morris Township
Employees: 201-500
Founded date: 1982
Investors 1
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
Mentions in press and media 6
| Date | Title | Description |
| 26.03.2025 | CBC Group hits first close on China’s largest healthcare buyout fund | CBC Group has raised over RMB 7 billion (USD 980 million) in the first close of its inaugural RMB-denominated healthcare buyout fund, with a target size of RMB 10 billion (USD 1.4 billion). The fund, which is now the largest of its kind in ... |
| 12.05.2020 | Chinese biotech aims $232M in IPO cash to push next-gen prostate cancer drug; Immunomedics raises nearly a half-billion off approval | → A Chinese cancer-focused biotech looking to one-up J&J and Pfizer in castration-resistant prostate cancer has launched its IPO in Hong Kong, looking to raise more than $232 million (HK$1.86 billion) on the HKEX. Three cor... |
| 18.01.2019 | Immunomedics must endure another delay as FDA rejects cancer drug citing manufacturing issues | We all like to root for the underdog. Following an arid spell stretching over three decades that in 2017 led to the ouster of Immunomedics founder/CSO and his CEO wife, the company (and analysts) were hopeful the drug develope... |
| 05.05.2017 | A $2B oncology deal goes bust at the hands of an activist investor | But behind the scenes, venBio wasn’t having any of it. The group moved quickly to get a 30-day hold on the agreement, arguing that it was not in the best interests of Immunomedics’ shareholders. “We announced the deal and very soon after th... |
| 15.03.2017 | Immunomedics lays out its case for an accelerated OK of IMMU-132 in triple-negative breast cancer | Aditya Bardia, Massachusetts General Hospital Cancer Center A little over a month after Seattle Genetics $SGEN snapped up the global rights to Immunomedics lead cancer drug IMMU-132 (sacituzumab govitecan) in a $2 bil... |
| - | A $2B oncology deal goes bust at the hands of an activist investor | Activist investor venBio had a good Friday. Seattle Genetics and Immunomedics did not. The two latter companies agreed to fold on their $2 billion oncology deal, while Immunomedics’ CEO and CSO also forfeited their jobs. First announced in ... |